News | November 08, 2024
Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Subscribe To Our Newsletter & Stay Updated
